Seribantumab
Based on 1 Customer Validation
Seribantumab (SAR256212; MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 96.043%
- CAS 番号: 1334296-12-6
- 分子量:143.14 kDa
-
保管条件:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
EGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Isotype
Human IgG2 lambda
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB3/HER3
体外実験
Seribantumab (0.1 nmol/L-10 μmol/L; 96 h) dose-dependently inhibits two cell lines that harbor NRG1 rearrangements (MDA-MB-175-VII, DOC4-NRG1 fusion and LUAD-0061AS3, SLC3A2-NRG1 fusion) with IC50 values of 0.02, 1.4, 45.2 and 203 μmol/L for MDA-MB-175-VII, LUAD-0061AS3, MCF-7 and HBECp53 cells, respectively[1]. Seribantumab (0.1, 1, and 10 μmol/L; 24-48 h) effectively inhibits growth of tumor cell lines that harbor NRG1 fusions or NRG1 amplification[1]. Seribantumab (0-0.5 μmol/L; 96 h) largely suppresses growth of NRG1-b1-stimulated MCF-7 cells[1]. Seribantumab (0-10 μmol/L; 48 h) induces apoptosis of cells harboring NRG1 rearrangements[1]. Seribantumab (0-10 μmol/L; 1 h) inhibits phosphorylation of downstream mediators in cells with NRG1 alterations[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-175-VII and LUAD-0061AS3 cell lines
-
Concentration:0-10 μmol/L
-
Incubation Time:48 hours
-
Result:Dose-dependently increased caspase 3/7 activity and induced apoptosis of NRG1 fusion-positive breast and lung cancer cell lines.
-
Cell Line:LUAD-0061AS3 and HBECp53-CD74-NRG1 cell lines
-
Concentration:0, 0.001, 0.01, 0.1, 1 and 10 μmol/L
-
Incubation Time:1 hour
-
Result:Inhibited the phosphorylation of EGFR, HER2, HER3, HER4, AKT and STAT3 in LUAD-0061AS3 cells. Completely inhibited HER3, AKT, p70S6K and STAT3, and reduced phosphorylation of HER2, EGFR and HER4 to a lesser extent in HBECp53-CD74-NRG1 cells.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunocompromised mice with LUAD-0061AS3 PDX tumors implanted[1]
-
Dosage:0.6, 0.75 and 1 mg
-
Administration:Intraperitoneal injection; 0.6, 0.75 and 1 mg for once
-
Result:Effectively reduced tumor growth of mice and time- and dose-dependently reduced phosphorylation of HER2, HER3, AKT, and ERK1/2. Induced the expression if proapoptotic protein, BIM.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG2 lambda
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized HER3 Protein, Human (HEK293, His, HY-P72625) can bind Seribantumab. The EC50 for this effect is 7.53 ng/mL. -
Flow cytometric analysis of 1X106 MCF-7 cells labeling Seribantumab (HY-P99268, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1334296-12-6
-
性状 Liquid
-
分子量 143.14 kDa
-
Color Colorless to light yellow
-
SMILES
[Seribantumab]
-
別名
SAR256212; MM 121
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)